

## SOPHARMA TRADING

### INDUSTRY: PHARMACEUTICAL WHOLESALE

#### THOSE PROFITS KEEP COMING

**LEADING BULGARIAN PHARMACEUTICAL WHOLESALER, SOPHARMA TRADING, DELIVERED EXCELLENT 9M 2015 RESULTS DESPITE CHALLENGING ENVIRONMENT AND SET THE ROOTS FOR FURTHER PORTFOLIO DIVERSIFICATION AND NEW POCKETS OF LONG TERM GROWTH.**

#### SUSTAINS TOP LINE GROWTH AND STEPS UP PROFITABILITY

In a market where every basis point is important the leading pharmaceutical wholesaler in Bulgaria, Sopharma Trading, delivered excellent bottom line results for the 9M 2015 and steady top line expansion. Sales were up 5% y/y to BGN 449.3 m, below expectations, but in more cautious market as pharmacy and hospital segment growth decelerated. The bottom line, however, considerably outperformed as high margin medical equipment and consumable sales rose 86% y/y to BGN 16.6m thanks to exclusive company portfolio. EBT increased 18.6% y/y to BGN 11.8m translating into 2.35% EBT margin.

#### DIVIDENDS KEEP COMING AND RISING

With a steady top line growth and improving bottom line, Sopharma Trading's dividend payments look on the rise. The company distributed 83.5% of 2014 net profit (BGN 0.27 DPS and 5% DY), above our estimates, and management seems firm at keeping those dividends coming. Accordingly, we revise upwards our 2015 DPS from BGN 0.30 to BGN 0.34 per share which yields a 6.45% return on current quotes. The latter seems sustainable as higher leverage is coupled with adequate debt/receivables management.

#### DIVERSIFYING TO ADD NEW POCKETS OF GROWTH AND PROFITS

With Bulgarian pharmaceutical market highly competitive and satiated, in 2015 Sopharma Trading made firm steps towards expanding into new horizons to further diversify and add new pockets of growth. It started developing its own SPharmacy retail chain, registered a subsidiary in Serbia to explore the wholesale and retail sector there and acquired an online pharma store to tap on booming e-commerce. Investments in the latter amount to BGN 1m and are yet to affect the company's results. In addition, the Company leverages its hospital segment expertise with its OMNIS project offering full "A to Z" hospital investment consulting services to investors in the sector.

#### HEALTHCARE REFORM IN BULGARIA POSES UNCERTAINTY

The new horizons move is also a way for Sopharma Trading to hedge any unfavorable healthcare system reshuffle in Bulgaria. Intense discussions on the latter are underway for months with the government proposing questionable reforms both in the underfunded healthcare system and in the competitive pharmacy market. The latter has affected investment activity in the sector, but Sopharma Trading delivered steady top line growth as continue EU funds in Bulgaria sustain growth in this sector as well.

**VALUATION:** Based on 9M 2015 results we revise downward our top line expectations but increase our bottom line estimates. These leads to a lower target price of BGN 6.12 per share vs. previous estimate of BGN 6.47 per share. Thus, we keep our BUY recommendation but lower our target price.

#### RESULTS ANALYSIS

**RECOMMENDATION: BUY**  
**ONE YEAR PRICE TARGET: BGN 6.12**  
**CURRENT PRICE: BGN 5.20**

**EXCHANGE RATES**  
**EUR/BGN (FIXED): 1.95583**  
**USD/BGN: 1.80995**

#### MARKET DATA

Shares Outstanding:	<b>32.9 m</b>
Share Capital:	<b>32.9 m</b>
Free-float:	<b>28%</b>
Treasury Shares	<b>0%</b>
Market Cap.:	<b>BGN 276 m</b>
52 Weeks Range:	<b>BGN 4.83 – 5.42</b>
Ave. Daily Turnover	<b>BGN 36, 000</b>
BSE Ticker	<b>S05</b>
Bloomberg Ticker	<b>S05 BU</b>

#### PRICE PERFORMANCE



Source: Bloomberg

in kBGN, excl. ratios	Q1 2014	Q2 2013	Q3 2014	Q4 2014	Q1 2015	Q2 2015	Q3 2015
REVENUES	143 998	141 903	141 771	148 428	153 079	143 523	152 646
GROWTH Y/Y	17.71%	17.60%	12.42%	7.62%	6.31%	1.14%	7.67%
EBITDA	4 408	4 609	3 911	2 911	4 613	3 650	5 914
EBIT	3 735	3 884	3 145	2 121	3 723	2 754	5 076
NET PROFIT	3 393	3 656	2 911	679	3 587	3 333	4 894
EQUITY	62 762	58 850	61 761	62 605	66 193	60 795	65 532
ROE (TTM)	17.38%	19.38%	18.62%	17.42%	17.35%	16.94%	19.71%
ROA (TTM)	4.49%	4.85%	4.61%	4.28%	4.27%	4.05%	4.76%
EBITDA MARGIN	3.06%	3.25%	2.76%	1.96%	3.01%	2.54%	3.87%
NET PROFIT MARGIN	2.36%	2.58%	2.05%	0.46%	2.34%	2.32%	3.21%
EPS	0.10	0.11	0.09	0.02	0.11	0.10	0.15
DEBT/EQUITY	1.60	1.66	1.69	1.77	1.70	1.87	1.71
P/E	14.31	14.27	16.06	16.32	15.31	16.55	13.56
P/B	2.37	2.80	2.93	2.77	2.51	2.86	2.59

## ANALYST'S COMMENTS

Sopharma Trading confirmed the perception of delivering steady results yet again with its performance for the 9M of 2015.

**Top line dissection:** The Company managed to deliver comfortable top line growth and a surge in the bottom line due to high margin medical equipment and consumables sales. Overall revenues grew by 5% y/y to BGN 449.3m with equipment and consumables sales alone up 86% y/y to BGN 16.6m. The Company is a market leader both in the pharmacy and hospitals segments in Bulgaria with a 17% and 41% market share, respectively. Overall market share stood at 21.67% as of Sept. 2015 with three major competitors on the pharmacy market.

The latter surge in equipment sales was due to a major project for the Sofia Hospital St. Ivan Rilski to which the Company delivered a high-tech linear accelerator and radiosurgery treatment system. The Company is also a supplier to the new hospital in Panyurishte, Central Bulgaria, an investment project estimated at BGN 55m that shall be operational by the end of 2015.

Nevertheless, overall top line grew below expectations as the market was more cautious and investment activity generally subdued due to the ongoing healthcare system reshuffle in Bulgaria. At this stage, discussions are still underway and no firm decisions have been taken but in general the government is proposing questionable reforms both in the underfunded and ineffective system and in the competitive pharmacy market. The former signals pro state-owned hospital changes while the latter aims at state involvement in the competitive pharmacy market.

Accordingly, Sopharma Trading was more cautious on the hospital segment of the market where it controls basically half of all medical deliveries. Hospital medicine segment sales grew slightly lower than a year earlier at 10.13% y/y with Sopharma Trading being cautious on new deliveries to municipal hospitals, especially outside the capital of Sofia. This coupled with price competition on the pharmacy market from a leading competitor, the Phoenix Pharma, led to a 1.89% y/y decrease in Sopharma Trading pharmacy segment sales for the 9M 2015.

**Bottom line break down:** Still, the top line performance translated into improved profitability both due to the better high margins sales and higher interest income on delayed receivables. Gross profit margin on equipment sales amounted to 30% for the 9M 2015 to BGN 4m, up 10pp from 2014A gross profit margin.

EBITDA is up 9.66% y/y to BGN 14.2 m despite an 8.87% y/y rise in labor costs due to 7% increase the number of employees transferred from the OTC product marketing team in Sopharma at the beginning of 2015. Also, overall top line growth was more than enough to offset the corresponding COGS rise as well as additional external services costs.


Half of its trade receivables are overdue, amounting to BGN 87.5m and coming from local state and municipal hospitals that have a long term history on delaying payments to suppliers. The Company charges interest and takes hospitals to court to collect receivables which it operationally funds with cheap bank financing. In 2015, the company made a profit from the respective interest income on those receivables, thus adding to the bottom line. Accordingly, earnings before profits is up 18.6% y/y to 11.8m which considerably outperforms our estimates and makes us comfortable to raise our 2015 profit forecasts.

Longer receivables collection due to hospital delays is the main reason for the higher leverage that the Company has taken on to fund operations and keep top line growth. For the 9M of 2015, the Company slightly decreased D/E from 177% in Dec. 2014 to 171% in Sept. 2015. Thus, we are more optimistic on the dividend payments in 2016 and raise our forecast from BGN 0.30 to BGN 0.34 dividend per share, yielding 6.45% as of current quotes. Supportive for our upward dividend revision is also the higher than expected dividend payout in 2015 a.k.a. 83.5% of 2014 profits or BGN 0.27 DPS, yielding 5% as of ex-dividend date quotes.

**Portfolio diversification** Another optimistic signal for us is Sopharma Trading's efforts to further diversify its portfolio. Its OMNIS project offering full "A to Z" hospital investment consulting services already bears fruits as the company has been a preferred partner for hospital investment and modernization, especially with its exclusive partnerships with GE, Abbot, Carl Zeiss, etc. The company is also exclusive distributor of a number of vitamins and other OTC products and plans to further tap on those by expanding to Serbia. Sopharma Trading established a marketing subsidiary in neighboring country and is currently exploring ways to tap on the less developed but bigger market. Also, the company started developing its own retail pharmacy chain, SOpharmacy, in Bulgaria with 4 pharmacies up and running and 8 more to come shortly. Lastly, in October the Company acquired an online pharmacy store, [www.farma.bg](http://www.farma.bg), to tap on the booming e-commerce and high demand for vitamins and food-additive products.


**Valuation revision:** Accordingly, we revise downward our bottom line estimates for 2015 and upward our 2015 profit estimate which lowers our one year target price from BGN 6.47 to BGN 6.12 per share. We still do not incorporate the Company's investments in portfolio diversification as they are yet to bear fruits. Nevertheless, we remain comfortable with our initial BUY recommendation and thus leave it unchanged.

### PORTFOLIO DIVERSIFICATION SUPPORTS PROFITABILITY



Source: Company data, Elana Trading estimates

### HOSPITALS GREW THE MOST IN 2015 DESPITE DIFFICULT ENVIRONMENT



Source: Company data

**ANNUAL FINANCIAL DATA (AUDITED)**

<b>INCOME STATEMENT ('000 BGN)</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>Q3 2014</b>	<b>Q3 2015</b>	<b>TTM</b>	<b>2015F</b>	<b>2016F</b>
<b>Sales</b>	<b>462 529</b>	<b>507 027</b>	<b>576 100</b>	<b>427 672</b>	<b>449 248</b>	<b>528 603</b>	<b>602 025</b>	<b>650 186</b>
Other operating income	4 106	3 315	4 794	3 464	3 959	3 810	4 696	5 071
Change in Inventories	0	0	0	0	0	0	0	0
Cost of Materials	3 127	2 973	3 364	2 522	2 240	2 691	3 311	3 901
Cost of External Services	5 790	5 962	7 918	5 632	7 354	7 684	8 127	8 452
Cost of Labor	12 715	13 685	15 578	11 560	12 858	14 983	16 255	17 685
Other operating expenses	4 131	6 030	2 570	1 193	1 723	6 560	4 515	4 876
COGS	430 800	470 987	535 625	397 301	414 855	488 541	556 271	598 172
Total Operating Expenses	457 983	499 794	568 009	420 372	441 654	521 076	591 489	636 663
<b>EBITDA</b>	<b>11 052</b>	<b>12 770</b>	<b>15 839</b>	<b>12 928</b>	<b>14 177</b>	<b>14 019</b>	<b>18 241</b>	<b>22 171</b>
Depreciation and Amortization	2 400	2 222	2 954	2 164	2 624	2 682	3 010	3 576
<b>EBIT</b>	<b>8 652</b>	<b>10 548</b>	<b>12 885</b>	<b>10 764</b>	<b>11 553</b>	<b>11 337</b>	<b>15 231</b>	<b>18 595</b>
Financial revenue	1 317	2 987	2 522	1 700	3 020	4 307	2 996	2 796
Financial expense	1 788	2 955	3 546	2 504	2 759	3 210	3 612	3 901
Interest Expense	1 479	1 861	2 998	2 182	2 311	1 990	2 769	2 926
<b>EBT</b>	<b>8 181</b>	<b>10 580</b>	<b>11 861</b>	<b>9 960</b>	<b>11 814</b>	<b>12 434</b>	<b>14 615</b>	<b>17 490</b>
Income Taxes	832	1 090	1 222	0	0	1 090	1 324	1 756
Minority Interest	0	0	0	0	0	0	0	0
<b>Net Income</b>	<b>7 349</b>	<b>9 490</b>	<b>10 639</b>	<b>9 960</b>	<b>11 814</b>	<b>11 344</b>	<b>13 290</b>	<b>15 735</b>
EARNINGS PER SHARE IN BGN	0.22	0.29	0.32	0.30	0.36	0.34	0.40	0.48
<b>BALANCE SHEET ('000 BGN)</b>	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>Q3 2014</b>	<b>Q3 2015</b>	<b>TTM</b>	<b>2015F</b>	<b>2016F</b>
Inventories	55 458	55 039	62 877	52 056	50 028	50 028	66 223	71 521
Receivables from related parties	838	2 620	2 232	2 237	2 215	2 215	1 806	1 951
Trade Receivables	131 515	141 889	151 058	170 232	176 062	176 062	162 547	169 048
Other receivables and prepaid expenses	556	2 816	866	3 041	1 879	1 879	3 010	3 251
Cash & Cash Equivalents	3 507	3 395	3 948	5 008	7 678	7 678	14 063	8 679
<b>TOTAL CURRENT ASSETS</b>	<b>191 874</b>	<b>205 759</b>	<b>220 981</b>	<b>232 574</b>	<b>237 862</b>	<b>237 862</b>	<b>247 649</b>	<b>254 449</b>
Property, Plant & Equipment	20 744	25 322	21 825	24 786	20 453	20 453	21 071	22 757
Intangibles	773	920	3 312	2 471	5 696	5 696	4 816	5 201
Investment property	0	0	0	0	0	0	0	0
Investments in subsidiaries	0	0	0	0	834	834	0	0
Investments available for sale	3 102	2 256	2 412	2 256	2 384	2 384	2 408	2 601
Receivables from related parties	0	0	0	0	800	800	0	0
Other receivables	0	306	258	205	295	295	361	390
<b>TOTAL LONG-TERM ASSETS</b>	<b>24 619</b>	<b>28 804</b>	<b>27 807</b>	<b>29 718</b>	<b>30 462</b>	<b>30 462</b>	<b>28 656</b>	<b>30 949</b>
<b>TOTAL ASSETS</b>	<b>216 493</b>	<b>234 563</b>	<b>249 014</b>	<b>262 557</b>	<b>268 657</b>	<b>268 657</b>	<b>276 305</b>	<b>285 398</b>
Short-term Bank Loans	47 066	89 573	105 218	98 138	107 464	107 464	107 160	104 030
Current Portion of Long Term Bank Loans	1 194	1 390	1 788	1 780	1 726	1 726	2 408	2 601
Liabilities to Related Parties	67 710	31 895	28 097	46 602	34 508	34 508	45 754	49 414
Account Payables	34 000	40 618	38 872	41 287	48 922	48 922	44 550	48 114
Tax Liabilities	1 154	1 559	3 241	3 652	3 571	3 571	1 806	1 951
Liabilities to Employees & Social Security	1 011	1 169	1 356	1 258	1 488	1 488	1 806	1 951
Other Current Liabilities	1 144	1 684	1 798	1 758	1 092	1 092	2 649	2 861
<b>TOTAL CURRENT LIABILITIES</b>	<b>153 279</b>	<b>167 888</b>	<b>180 370</b>	<b>194 475</b>	<b>198 771</b>	<b>198 771</b>	<b>206 133</b>	<b>210 920</b>
Long Term Bank Loans	3 008	5 539	3 837	4 279	2 547	2 547	2 408	2 601
Deferred Taxes	320	0	0	0	0	0	271	325
Liabilities to Employees on Retirement	189	251	316	251	332	332	241	260
Financial Leases	968	1 498	1 651	1 515	1 140	1 140	1 264	1 365
Other Long Term Liabilities	27	18	9	11	2	2	60	65
<b>TOTAL LONG-TERM LIABILITIES</b>	<b>4 512</b>	<b>7 306</b>	<b>5 813</b>	<b>6 056</b>	<b>4 021</b>	<b>4 021</b>	<b>4 244</b>	<b>4 616</b>
<b>TOTAL LIABILITIES</b>	<b>157 791</b>	<b>175 194</b>	<b>186 183</b>	<b>200 531</b>	<b>202 792</b>	<b>202 792</b>	<b>210 377</b>	<b>215 537</b>
Share Capital	32 905	32 905	32 905	32 905	32 905	32 905	32 905	32 905
Reserves	18 244	16 691	17 111	18 526	18 836	18 836	18 440	20 013
Retained Earnings	7 553	9 773	12 589	10 330	13 791	13 791	14 583	16 943
<b>TOTAL EQUITY</b>	<b>58 702</b>	<b>59 369</b>	<b>62 605</b>	<b>61 761</b>	<b>65 532</b>	<b>65 532</b>	<b>65 928</b>	<b>69 861</b>
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>216 493</b>	<b>234 563</b>	<b>248 788</b>	<b>262 292</b>	<b>268 324</b>	<b>268 324</b>	<b>276 305</b>	<b>285 398</b>
	<b>2012</b>	<b>2013</b>	<b>2014</b>	<b>Q3 2014</b>	<b>Q3 2015</b>	<b>TTM</b>	<b>2015F</b>	<b>2016F</b>
<b>NUMBER OF SHARES:</b>	32 905 009	32 905 009	32 905 009	32 905 009	32 905 009	32 905 009	32 905 009	32 905 009
<b>PRICE IN BGN - PERIOD END:</b>	1.78	3.20	5.50	2.83	5.20	5.20	5.20	5.20
<b>MARKET CAP IN BGN - PERIOD END:</b>	58 570 916	105 296 029	180 977 550	93 121 175	171 106 047	171 106 047	171 106 047	171 106 047

Source: Company financial statements, ELANA Trading forecasts

**QUARTERLY FINANCIAL DATA (UNAUDITED)**

INCOME STATEMENT ('000 BGN)	Q3 2013	Q4 2013	Q1 2014	Q2 2014	Q3 2014	Q4 2014	Q1 2015	Q2 2015	Q3 2015
<b>Sales</b>	<b>126 106</b>	<b>137 921</b>	<b>143 998</b>	<b>141 903</b>	<b>141 771</b>	<b>148 428</b>	<b>153 079</b>	<b>143 523</b>	<b>152 646</b>
Other operating income	-409	863	1 254	1 053	1 157	1 330	1 053	1 946	960
Change in Inventories	0	0	0	0	0	0	0	0	0
Cost of Materials	718	779	818	879	825	842	678	917	645
Cost of External Services	1 456	1 505	2 075	1 442	2 115	2 286	2 113	2 277	2 964
Cost of Labor	3 339	3 482	3 525	4 226	3 809	4 018	4 054	4 632	4 172
Other operating expenses	1 466	2 899	317	632	244	1 377	344	519	860
COGS	115 578	128 430	141 517	131 168	132 024	138 324	142 330	133 474	139 051
<b>EBITDA</b>	<b>3 675</b>	<b>2 848</b>	<b>4 408</b>	<b>4 609</b>	<b>3 911</b>	<b>2 911</b>	<b>4 613</b>	<b>3 650</b>	<b>5 914</b>
Depreciation and Amortization	354	517	673	725	766	790	890	896	838
<b>EBIT</b>	<b>3 321</b>	<b>2 331</b>	<b>3 735</b>	<b>3 884</b>	<b>3 145</b>	<b>2 121</b>	<b>3 723</b>	<b>2 754</b>	<b>5 076</b>
Financial revenue	393	829	510	619	571	822	800	1 483	737
Financial expense	541	763	852	847	805	1 042	936	904	919
<b>EBT</b>	<b>3 173</b>	<b>2 397</b>	<b>3 393</b>	<b>3 656</b>	<b>2 911</b>	<b>1 901</b>	<b>3 587</b>	<b>3 333</b>	<b>4 894</b>
Income Taxes	0	1 090	0	0	0	1 222	0	0	0
<b>Net Income</b>	<b>3 173</b>	<b>1 307</b>	<b>3 393</b>	<b>3 656</b>	<b>2 911</b>	<b>679</b>	<b>3 587</b>	<b>3 333</b>	<b>4 894</b>

BALANCE SHEET ('000 BGN)	Q3 2013	Q4 2013	Q1 2014	Q2 2014	Q3 2014	Q4 2014	Q1 2015	Q2 2015	Q3 2015
CASH & NEAR CASH ITEMS	3 507	5 253	9 085	6 894	3 395	6 824	4 344	5 008	3 948
ACCOUNTS & NOTES RECEIVABLE	131 515	140 375	140 784	137 846	141 889	153 413	163 305	170 232	151 058
INVENTORIES	55 458	44 896	45 820	41 583	55 039	51 931	53 596	52 056	62 877
OTHER CURRENT ASSETS	1 394	11 822	10 794	15 391	5 436	3 474	4 178	5 278	3 098
<b>TOTAL CURRENT ASSETS</b>	<b>191 874</b>	<b>202 346</b>	<b>206 483</b>	<b>201 714</b>	<b>205 759</b>	<b>215 642</b>	<b>225 423</b>	<b>232 574</b>	<b>220 981</b>
NET FIXED ASSETS	21 517	23 129	22 919	22 247	26 242	25 774	26 315	27 257	25 137
OTHER LONG-TERM ASSETS	3 102	0	0	0	2 256	2 256	2 256	2 256	2 412
TOTAL LONG-TERM ASSETS	24 619	23 129	22 919	22 247	28 804	28 301	28 819	29 718	27 807
<b>TOTAL ASSETS</b>	<b>216 493</b>	<b>225 475</b>	<b>229 402</b>	<b>223 961</b>	<b>234 563</b>	<b>243 943</b>	<b>254 242</b>	<b>262 292</b>	<b>248 788</b>
ACCOUNTS PAYABLE	34 000	31 691	35 485	35 249	40 618	39 661	37 122	41 287	38 872
SHORT-TERM BORROWINGS	48 260	51 314	50 141	90 900	90 963	95 061	93 191	99 918	107 006
OTHER SHORT-TERM LIABILITIES	71 019	75 557	80 860	34 015	36 307	39 479	58 838	53 270	34 492
<b>TOTAL CURRENT LIABILITIES</b>	<b>153 279</b>	<b>158 562</b>	<b>166 486</b>	<b>160 164</b>	<b>167 888</b>	<b>174 201</b>	<b>189 151</b>	<b>194 475</b>	<b>180 370</b>
LONG-TERM BORROWINGS	3 976	5 274	5 731	5 545	7 037	6 713	5 977	5 794	5 488
OTHER LONG TERM BORROWINGS	536	534	531	529	269	267	264	262	325
TOTAL LONG-TERM LIABILITIES	4 512	5 808	6 262	6 074	7 306	6 980	6 241	6 056	5 813
<b>TOTAL LIABILITIES</b>	<b>157 791</b>	<b>164 370</b>	<b>172 748</b>	<b>166 238</b>	<b>175 194</b>	<b>181 181</b>	<b>195 392</b>	<b>200 531</b>	<b>186 183</b>
<b>TOTAL EQUITY</b>	<b>58 702</b>	<b>61 105</b>	<b>56 654</b>	<b>59 818</b>	<b>59 369</b>	<b>62 762</b>	<b>58 850</b>	<b>61 761</b>	<b>62 605</b>
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>216 493</b>	<b>225 475</b>	<b>229 402</b>	<b>226 056</b>	<b>234 563</b>	<b>243 943</b>	<b>254 242</b>	<b>262 292</b>	<b>248 788</b>

FINANCIAL AND PERFORMANCE INDICATORS	2012	2013	2014	TTM	2015F	2016F
<b>Valuation</b>						
Price/Earnings (P/E)	7.97	11.10	17.01	15.08	12.87	10.87
Price/Book (P/B)	1.00	1.77	2.89	2.61	2.60	2.45
EV (in '000 BGN)	107 300	199 901	289 524	276 305	270 284	273 024
EV/EBITDA	9.71	15.65	18.28	19.71	14.82	12.31
<b>Profitability</b>						
ROE	12.52%	15.98%	16.99%	17.31%	20.16%	22.52%
ROA	3.39%	4.05%	4.28%	4.23%	4.81%	5.51%
EBITDA margin	2.39%	2.52%	2.75%	2.65%	3.03%	3.41%
EBIT margin	1.87%	2.08%	2.24%	2.14%	2.53%	2.86%
Net income margin	1.59%	1.87%	1.85%	2.15%	2.21%	2.42%
<b>Dividend</b>						
Dividend yield	7.69%	4.51%	5.09%	4.42%	6.45%	7.63%
Dividend per share (BGN)	0.20	0.23	0.27	n/a	0.34	0.40
<b>Liquidity</b>						
Current ratio	1.25	1.23	1.23	1.20	1.20	1.21
Quick ratio	0.89	0.90	0.88	0.94	0.88	0.87
<b>Credit</b>						
LT debt/equity	0.05	0.09	0.06	0.04	0.04	0.04
Total debt/equity	0.87	1.63	1.77	1.71	1.70	1.56
Total debt/total assets	0.73	0.75	0.75	0.76	0.76	0.76

**COMPANY OVERVIEW**

**SOPHARMA TRADING Overview**

<b>Ticker</b>	S05	<b>Recommendation</b>	BUY	<b>Outstanding Shares</b>	32.9 m
<b>Bloomberg ticker</b>	S05 BU	<b>Last review</b>	10 December 2015	<b>Free Float</b>	28%
<b>Current Price</b>	BGN 5.20	<b>1Y Target Price</b>	6.12	<b>Ave. Daily Turnover</b>	BGN 36,000

**COMPANY PROFILE**

Sopharma Trading is the leading Bulgarian pharmaceutical distributor with a 22% market share. The company is part of the Sopharma group that integrates one of the leading generic and organic pharmaceutical producer in the country – Sopharma (3JR BU), together with other supporting operations.

Sopharma Trading is a full-value healthcare solutions provider with 3000+ customers, 10,000+ diversified product portfolio and 400 local and international partners, including with exclusive contracts with GE Healthcare, Abbott, Carl Zeiss, Aboca, etc.

It holds 17% of the local pharmacy market and 41% of the local hospitals' market. The former, however, still contributes the most to the company's top line, while the latter and the medical equipment sales add to its bottom line.

The company manages modern logistics system with four regional distribution centers, 17 500 sq. m., in four of the biggest cities in Bulgaria. Its pharmaceutical logistics terminal in Sofia, the biggest of the four, operates with a state of the art KNAPP warehouse management system. The Company is Good Distribution Practice certified.

**FUNDAMENTAL STORY**


Sopharma Trading's leading position on the local pharmaceutical distribution market provides grounds for high long term sustainable growth as the local market is growing at 5%+ y/y and the local healthcare system is well underdeveloped as compared to EU average.

Bulgarian hospitals are in dire need of modernization both as facilities and equipment and use EU funds to accomplish it. Additionally, government healthcare spending is 80% below EU average thus offering considerable potential for growth from which Sopharma Trading will be able to benefit to the most as it holds 41% of the local hospital market. Also, it is one of the few exclusive medical equipment distributors.


**STRENGTHS & OPPORTUNITIES**

- Excellent corporate governance
- Strong market positions despite heavy competition
- Stable dividend policy

**SHAREHOLDERS' STRUCTURE**



**SALES GROWTH**



SOURCE: COMPANY DATA, ELANA TRADING ESTIMATES

**WEAKNESSES & THREATS**

- Heavy exposure to state-owned hospitals which are characterized with huge delays in payments
- High Debt/Equity as the company acts as a creditor to Bulgarian hospitals



## Disclaimer

**Regulatory Restrictions:** No publication of ELANA Trading should be construed as an offer (or solicitation of an offer) to **U.S. persons** to buy or sell financial instruments or any financial product, make any investment or participate in any particular trading strategy (collectively "Offers"). No Publication of ELANA Trading should be construed as an Offer (or solicitation of an offer) in any jurisdiction in which such Offer would be illegal. Any such perceived Offer will not be honoured by ELANA Trading.

**Analyst Certification:** The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

**Financial Interest:** ELANA trading does and seeks to do business with companies covered in its research reports. This may and includes investment banking services for which ELANA Trading shall be remunerated. ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted. As a result, investors should be aware that ELANA trading may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

**Regulatory Authority:** Financial Supervisory Commission, *Budapest Street 16, 1000 Sofia, Bulgaria*

**Information Disclosure:** All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

**Risks for Investors:** Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

**Valuation Methods:** Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

**Recommendations:** Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

<b>BUY</b>	Target price is more than 10% above current quotes
<b>HOLD</b>	Target price in +/-10% range of the current quotes
<b>SELL</b>	Target price is more than 10% below the current quotes

**Frequency of Recommendations:** No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

**Copyrights:** The copyrights of ELANA Trading analyses belong to the Research Department of the brokerage and their content cannot be used for commercial purposes. Replication and redistribution of ELANA Trading analyses content is expressly prohibited without the prior written consent of the appointed contacts listed below.

## For more information, please contact:

Research analyst	Phone:	E-mail:	Internet:
<b>Tatyana Vasileva</b>	<b>+359 2 810 00 24</b>	<a href="mailto:vasileva@elana.net">vasileva@elana.net</a>	<a href="http://www.elana.net">www.elana.net</a>
<b>Georgi Penchev</b>	<b>+359 2 810 00 27</b>	<a href="mailto:penchev@elana.net">penchev@elana.net</a>	<a href="http://www.elana.net">www.elana.net</a>